CN

Company news

Location：

Home

News

Company news

Chairman Lv Xiangyang attended the 4th Financial Planner Festival of Manqian Technology and delivered a speech

Categories:Company news
Author:
Origin:
Time of issue:2021-01-20
Views:0





Chairman Lv Xiangyang attended the 4th Financial Planner Festival of Manqian Technology and delivered a speech

(Summary description)On September 7, 2019, the 4th Financial Planner Festival hosted by Manqian Technology was grandly held in Shenzhen. Manqian Technology is the first financial technology company to propose the TAMP model in China, and it is an important part of the financial investment sector of Youngy Group.

Categories:Company news
Author:
Origin:
Time of issue:2021-01-20
Views:0

Information

On September 7, 2019, the 4th Financial Planner Festival hosted by Manqian Technology was grandly held in Shenzhen. Manqian Technology is the first financial technology company to propose the TAMP model in China, and it is an important part of the financial investment sector of Youngy Group.

Scan the QR code to read on your phone

Previous: Forge ahead and promote research and development, group leaders come to REGENECORE to guide the work

Next: Yu Aihua, member of the Standing Committee of Anhui Provincial Party Committee and secretary of Hefei Municipal Party Committee, held talks with Lv Xiangyang

Previous: Forge ahead and promote research and development, group leaders come to REGENECORE to guide the work

Next: Yu Aihua, member of the Standing Committee of Anhui Provincial Party Committee and secretary of Hefei Municipal Party Committee, held talks with Lv Xiangyang

12-02

2024



融捷集团：竞逐新(xīn)赛道，勇攀生命科(kē)技(jì )高峰

近日，南京融捷康生物(wù)科(kē)技(jì )有(yǒu)限公(gōng)司发布的一则招募中(zhōng)重度哮喘患者的消息引人关注。原来，由融捷康自研的國(guó)内首个自免双特异性纳米抗體(tǐ)药物(wù)——RC1416注射液，正在全國(guó)数十家知名(míng)医(yī)院开展临床研究。这款双抗药品在药效、安(ān)全性和成药性等多(duō)重指标上具(jù)有(yǒu)较好的优势，未来有(yǒu)望成為(wèi)中(zhōng)重度哮喘患者的福音。

11-26

2024



Recruitment of Patients with Moderate to Severe Asthma

RC1416 injection, developed by Nanjing RegeneCore Biotech Co.,Ltd, is currently undergoing a Phase Ib clinical study to "evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary effectiveness of RC1416 injection in patients with moderate to severe asthma." The lead institution for this study is the China-Japan Friendship Hospital in Beijing, and it is simultaneously being conducted at dozens of renowned hospitals across the country.

09-19

2024



Lv Xiangyang Visited Nanjing Regenecore and Thoth Institutes

Lv Xiangyang visited Nanjing Regenecore & Thoth Institutes, assessing developments & future development direction.

TEL：

025-58608860

Address: Room 07 Building 16 Treehouse, No. 73, Tanmi Road, Jiangbei New District, Nanjing

Enterprise email：rjk@regenecore.com

WeChat cooperative consultation

www.300.cn nanjing 备案号：京ICP证000000号

You are the th visitor